Wahl Receives SNMMI Transformative Leadership Award
Richard L. Wahl, MD, professor of radiology for Mallinckrodt Institute of Radiology (MIR) and principal investigator in the Precision Radiotheranostics Translation Center at Washington University School of Medicine in St. Louis, received the Minoshima-Pappas Transformational Leadership Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The award recognizes an individual who has made significant and transformative contributions to the field.
Wahl has contributed to several advances in nuclear medicine and imaging, most notably by developing the first FDA-approved radioimmunotherapies for non-Hodgkin’s lymphoma. He also pioneered using PET imaging to assess a wide range of cancers. His work has also resulted in several FDA-approved drugs and devices that use radioactive tracing compounds to bind to specific proteins to diagnose and treat cancers. During his tenure as SNMMI president, Wahl founded the Mars Shot Fund to help revolutionize the future of patient care through groundbreaking scientific discoveries.
“Dr. Wahl is a true visionary in the field of nuclear medicine and molecular imaging,” said Virginia Pappas, SNMMI chief executive officer in a press release. “As a physician-scientist, his research has helped pave the way for clinical advances in diagnosing cancer and other diseases. What’s more, his unwavering dedication to eliminating barriers has helped countless patients to access these powerful diagnostic tools and therapies.”
Wahl accepted the award during a ceremony at the SNMMI 2024 Annual Meeting in Toronto, Ontario, Canada.
